Organization
Meridigen Biotech
6 clinical trials
Clinical trial
The Safety and Feasibility of UMC119-01 Cell Therapy in Infants at High Risk for Bronchopulmonary DysplasiaStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
The Safety and Tolerability After Intravenous Infusion of UMC119-06 in Subjects With Acute Ischemic Stroke.Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety and Tolerability After Intravenous Infusion of UMC119-06-05 in Elderly Subjects With Mild to Moderate Frailty Syndrome.Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
The Safety and Tolerability After Intravenous Infusion of UMC119-06 in Subjects With Acute Respiratory Distress Syndrome (ARDS).Status: Not yet recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 1, Open Label, Dose Escalation Study to Evaluate the Safety and Tolerability After Intra Articular (IA) Injection of UMC119-06-05 in Adult Subjects With Mild to Moderate Knee Osteoarthritis(KOA).Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
The Safety and Feasibility of UMC119-06 Cell Therapy in Subjects With Chronic Obstructive Pulmonary DiseaseStatus: Active (not recruiting), Estimated PCD: 2023-12-31